Clinical trial
A Study of Enzastaurin in Patients With Leukemia
NCT00452257 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00452257 |
|---|---|
| Title | A Study of Enzastaurin in Patients With Leukemia |
| Official title | A Phase 1b Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic |
| Intervention type | Drug |
| Interventions | enzastaurin |
| Enrollment | 18 |
| Start date | May 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Mar 27, 2007 |
| Last update posted | Mar 19, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: